Effects of Long-term Norfloxacin Therapy in Patients with Advanced Cirrhosis.

Date publication

août 2018

Journal

Gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Pr DI MARTINO Vincent

Tous les auteurs :
Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30144431

Résumé

There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis.

Mots clés

Inflammation, Liver-Related Complications, NORFLOCIR Trial, Risk Factor

Référence

Gastroenterology. 2018 Aug 22;: